Patents by Inventor Kiyonori Katsuragi
Kiyonori Katsuragi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12018324Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.Type: GrantFiled: April 25, 2018Date of Patent: June 25, 2024Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori Katsuragi, Hideaki Tanaka, Ryuta Ito, Daisuke Koga
-
Publication number: 20200377928Abstract: The disclosure provides a method comprising (1) conducting a PCR using a nucleic acid sample obtained from the subject as the template, a forward primer having a nucleic acid sequence of a part of exon 1 of the BCR gene, and a reverse primer having a nucleic acid sequence complementary to a part of exons 2 to 11 of the ABL1 gene, in the presence of a modified nucleic acid having a nucleic acid sequence of a part of exons 2 to 14 of the BCR gene or a nucleic acid sequence complementary thereto; and (2) determining that the subject has the minor BCR-ABL1 gene when the nucleic acid amplification is occurred in the PCR.Type: ApplicationFiled: April 25, 2018Publication date: December 3, 2020Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori KATSURAGI, Hideaki TANAKA, Ryuta ITO, Daisuke KOGA
-
Patent number: 10538812Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.Type: GrantFiled: November 13, 2015Date of Patent: January 21, 2020Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori Katsuragi, Moritoshi Kinoshita, Daisuke Koga, Ryo Higashiyama
-
Publication number: 20190257842Abstract: An object of the invention is to provide a method for assisting diagnosis of Alzheimer's disease (AD), and a detection reagent, a diagnosis kit and a diagnosis system for use in the method. Provided is a method for assisting diagnosis of AD, comprising the steps of: measuring an amount of a urine biomarker in a urine sample derived from urine collected from a subject; and determining whether the subject suffers from AD or has a high risk of developing AD based on the amount of the urine biomarker measured, wherein the urine biomarker is at least one urine protein selected from the group consisting of ApoA-I, ApoA-II, ApoA-IV, ApoB-100, ApoB-48, ApoC-I, ApoC-II, ApoC-III, ApoD, ApoE, IFITM1, IFITM2, IFITM3, NPC1, NPC2, NPC1L1, and MT.Type: ApplicationFiled: August 3, 2017Publication date: August 22, 2019Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori KATSURAGI, Kiyotaka MACHIDA, Hirokazu KARIYAZONO, Ryo HIGASHIYAMA, Hironori KOBATASHI, Yoko SAIJO, Ayumi SATO
-
Patent number: 9933442Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.Type: GrantFiled: October 7, 2014Date of Patent: April 3, 2018Assignee: LSI MEDIENCE CORPORATIONInventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
-
Publication number: 20180037955Abstract: The present invention provides a means for efficiently amplifying the exons of PKD1 and PKD2 genes, and a primer set that can amplify all the exons of PKD1 and PKD2 genes under a single set of PCR conditions.Type: ApplicationFiled: November 13, 2015Publication date: February 8, 2018Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori KATSURAGI, Moritoshi KINOSHITA, Daisuke KOGA, Ryo HIGASHIYAMA
-
Patent number: 9851356Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.Type: GrantFiled: September 13, 2012Date of Patent: December 26, 2017Assignees: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Haruo Sugiyama, Yusuke Oji, Kiyonori Katsuragi, Hideaki Tanaka, Shinji Sogo, Yoshihiro Goto, Yasukazu Ohmoto, Husako Iwata
-
Publication number: 20170138958Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.Type: ApplicationFiled: December 8, 2016Publication date: May 18, 2017Applicants: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC., OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Haruo SUGIYAMA, Yusuke OJI, Kiyonori KATSURAGI, Hideaki TANAKA, Shinji SOGO, Yoshihiro GOTO, Yasukazu OHMOTO, Husako IWATA
-
Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
Patent number: 9512206Abstract: The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence set foType: GrantFiled: February 28, 2013Date of Patent: December 6, 2016Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori Katsuragi, Masataka Togashi, Tetsuya Oda, Ryuta Ito, Chie Kawaguchi, Yoko Saijo, Daisuke Koga, Makoto Matsumoto, Mamoru Fujiwara, Kenji Ono -
ANTI-LIPOARABINOMANNAN ANTIBODY AND IMMUNOASSAY FOR ACID-FAST BACILLARY INFECTION USING THE ANTIBODY
Publication number: 20160083458Abstract: The present invention provides a monoclonal antibody that specifically binds to acid-fast bacillary lipoarabinomannan, particularly tubercle bacillary lipoarabinomannan, the antibody being set forth below: (A) a monoclonal antibody comprising a heavy chain variable region and a light chain variable region joined via a linker, the heavy chain variable region comprising heavy chains CDR1 to CDR3 shown in (a) to (c) below, and the light chain variable region comprising light chains CDR1 to CDR3 shown in (d) to (f) below: (a) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 1, (b) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 2, (c) heavy chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 3, (d) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 4, (e) light chain CDR1 consisting of the amino acid sequence set forth in SEQ ID NO: 5, and (f) light chain CDR1 consisting of the amino acid sequence setType: ApplicationFiled: February 28, 2013Publication date: March 24, 2016Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Kiyonori KATSURAGI, Masataka TOGASHI, Tetsuya ODA, Ryuta ITO, Chie KAWAGUCHI, Yoko SAIJO, Daisuke KOGA, Makoto MATSUMOTO, Mamoru FUJIWARA, Kenji ONO -
Publication number: 20150025226Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Inventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
-
Patent number: 8871518Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.Type: GrantFiled: May 6, 2010Date of Patent: October 28, 2014Assignees: Otsuka Pharmaceutical Co., Ltd., LSI Medience CorporationInventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
-
Publication number: 20140227799Abstract: Provided is an invention relating to a method for measuring an anti-WT1 antibody in a sample allowing measurement and evaluation of the anti-WT1 antibody with higher accuracy and to use of the method.Type: ApplicationFiled: September 13, 2012Publication date: August 14, 2014Applicants: OTSUKA PHARMACEUTICAL CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Haruo Sugiyama, Yusuke Oji, Kiyonori Katsuragi, Hideaki Tanaka, Shinji Sogo, Yoshihiro Goto, Yasukazu Ohmoto, Husako Iwata
-
Publication number: 20120052596Abstract: A monoclonal antibody that does not show a crossreactivity with middle-molecular weight (MMW) adiponectin and specifically reacts with high-molecular weight (HMW) adiponectin alone is disclosed. The monoclonal antibody of the present invention can be produced by using HMW adiponectin as an antigen. According to the monoclonal antibody of the present invention, a convenient, high-accurate, and versatile reagent for analyzing HMW adiponectin can be provided.Type: ApplicationFiled: May 6, 2010Publication date: March 1, 2012Applicants: Otsuka Pharmaceutical Co., Ltd., Mitsubishi Chemical Medience CorporationInventors: Suguru Akamatsu, Kiyonori Katsuragi, Hideaki Onishi, Midori Abe, Toru Hadama, Ayako Nishimura, Mio Ooguchi
-
Patent number: 7368277Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.Type: GrantFiled: March 13, 2003Date of Patent: May 6, 2008Assignee: Otsuka Pharmaceutical Factory, Inc.Inventors: Tetsuya Tachikawa, Atsunari Noda, Kiyonori Katsuragi
-
Publication number: 20030175699Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.Type: ApplicationFiled: March 13, 2003Publication date: September 18, 2003Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Tetsuya Tachikawa, Atsunari Noda, Kiyonori Katsuragi
-
Publication number: 20020187510Abstract: The invention relates to a technology by which antibodies directed to sources of infection in body fluids can be assayed with high accuracy, expediency and specificity. More particularly, the invention provides an antibody immunoassay method in which the antigen-antibody reaction between a target antibody in a sample and an assay antigen is conducted in the presence of an E. coli component and an antibody assay method which comprises using a reagent having a specific affinity for the Fc region of an antibody IgG as the antibody assay reagent.Type: ApplicationFiled: December 9, 1999Publication date: December 12, 2002Inventors: TETSUYA TACHIKAWA, ATSUNARI NODA, KIYONORI KATSURAGI
-
Patent number: 5719026Abstract: The present invention provides a method for detecting polymorphism of the human cytochrome P4501A2 (CYP1A2) gene in which substitution at a 2064th base, substitution at a 2640th base, and/or deletion of a -1569th base in a nontranslational region of the human cytochrome P4501A2 gene are/is detected. According to the method of the invention, new types of polymorphism of the CYP1A2 gene can be detected simply and easily with high sensitivity and accuracy, and the method requires only a small amount of a DNA sample.Type: GrantFiled: March 6, 1996Date of Patent: February 17, 1998Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Takafumi Fukui, Kiyonori Katsuragi, Moritoshi Kinoshita, Sadahito Shin, deceased
-
Patent number: 5527677Abstract: The invention provides polymorphic human arylamine N-acetyltransferase (NAT) genes, more precisely a type 1 NAT gene containing the 5'-noncoding region base sequence of SEQ ID NO:1 and the coding region-containing base sequence of SEQ ID NO:2, a type 2 NAT gene containing the sequences of SEQ ID NO:3 and SEQ ID NO:4 and a type 3 NAT gene containing the sequences of SEQ ID NO:5 and SEQ ID NO:6, as well as a method of detecting these polymorphic genes and a method of diagnosing an adverse effect or effects to be caused by an amino-containing aromatic substance.Type: GrantFiled: October 11, 1994Date of Patent: June 18, 1996Assignees: Tokyo Metropolitan Institute for Neuroscience, Otsuka Pharmaceutical Co., Ltd.Inventors: Takeo Deguchi, Moritoshi Kinoshita, Kiyonori Katsuragi, Sadahito Shin